ELAC2
Reactivity: Human
IF (cc), IF (p)
Host: Rabbit
Polyclonal
AbBy Fluor® 750
Application Notes
Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: IHC 1:100-1:300,ELISA 1:10000,IF 1:50-200
Restrictions
For Research Use only
Format
Liquid
Concentration
1 mg/mL
Buffer
Liquid in PBS containing 50 % glycerol, 0.5 % BSA and 0.02 % sodium azide.
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
-20 °C
Storage Comment
Stable for one year at -20°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot to avoid repeated freezing and thawing.
Expiry Date
12 months
Target
ELAC2
(ElaC Homolog 2 (ELAC2))
Alternative Name
RNase Z2
Background
ELAC2, HPC2, Zinc phosphodiesterase ELAC protein 2, ElaC homolog protein 2, Heredity prostate cancer protein 2, Ribonuclease Z 2, RNase Z 2, tRNA 3 endonuclease 2, tRNase Z 2The protein encoded by ELAC2 (elaC ribonuclease Z 2) has a C-terminal domain with tRNA processing endoribonuclease activity, which catalyzes the removal of the 3' trailer from precursor tRNAs. The protein also interacts with activated Smad family member 2 (Smad2) and its nuclear partner forkhead box H1 (also known as FAST-1), and reduced expression can suppress transforming growth factor-beta induced growth arrest. Mutations in ELAC2 result in an increased risk of prostate cancer. Multiple transcript variants encoding different isoforms have been found for ELAC2.